parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.10 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in decidual stromal cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	1 Parkinson's trial, 0 stopped	1.00
literature PubMed	15 Parkinson's papers of 668	0.64
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 2705

receipt 2714: APOD in dopamine neurons, braak

power: full sample +0.09 (p 0.728, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.40 (p 0.099, n 18). could be the mix.
skeptic: leave-one-out range -0.03 to +0.17, sign flips 3; without severely affected donors +0.09 (p 0.728, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for APOD in dopamine neurons.

case closed: nothing better to follow up.

receipt 2713: APOD in oligodendrocytes, braak

power: full sample +0.17 (p 0.504, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.09 (p 0.735, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.30 (p 0.225, n 18). could be the mix.
skeptic: leave-one-out range +0.06 to +0.30, sign flips 0; without severely affected donors +0.17 (p 0.504, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for APOD in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts